menu
    • menu
    [{"orgOrder":0,"company":"Biomm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biomm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biomm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ Not Applicable"},{"orgOrder":0,"company":"Biomm","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Oncology","graph2":"Phase III","graph3":"Biomm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biomm \/ Lupin","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ Lupin"},{"orgOrder":0,"company":"Biomm","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Biomm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biomm \/ Biomm","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ Biomm"},{"orgOrder":0,"company":"Biomm","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Partnership","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biomm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomm \/ Biomm","highestDevelopmentStatusID":"12","companyTruncated":"Biomm \/ Biomm"}]

    Find Clinical Drug Pipeline Developments & Deals by Biomm

    Menu

    Biomm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biomm

                            Brazil arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Biomm

                            Brazil arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Recipient : Biocon

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Biocon Partners Biomm to Commercialise Diabetes Drug in Brazil

                            Details : Biocon will undertake the development, manufacturing and supply of Ozempic (semaglutide) and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazil.

                            Brand Name : Ozempic

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            April 17, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Recipient : Biocon

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biomm

                            Brazil arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Biomm

                            Brazil arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Bio-Thera Solutions

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, a Stelara® Biosimilar

                            Details : Under the agreement, Biomm will have exclusive rights to distribute and market BAT2206 (ustekinumab), a proposed biosimilar to Janssen’s Stelara, in Brazil for the treatment of active psoriatic arthritis.

                            Brand Name : BAT2206

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 16, 2023

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Bio-Thera Solutions

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biomm

                            Brazil arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Biomm

                            Brazil arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lupin and Biomm Enter into a Distribution and Marketing Agreement for Pegfilgrastim in Brazil

                            Details : Under the terms of agreement, Biomm will distribute and market biosimilar Pegfilgrastim in Brazil. Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.

                            Brand Name : Lupifil-P

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 03, 2021

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biomm

                            Brazil arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Biomm

                            Brazil arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leronlimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVI...

                            Details : Marketed as Vyrologix, leronlimab is an investigational humanised immunoglobulin G4 monoclonal antibody that hinders C-C chemokine receptor type 5 (CCR5).

                            Brand Name : Vyrologix

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 27, 2021

                            Lead Product(s) : Leronlimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth